Small Molecule Potentiator Program
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Key Facts
About Renasant Bio
Renasant Bio is an early-stage, privately-held biotech focused on developing first-in-class, disease-modifying therapies for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company's strategy involves two complementary small molecule modalities: correctors to stabilize and properly traffic misfolded PC1/2 proteins, and potentiators to enhance the function of the polycystin ion channel. Backed by a $54.5 million Series A and a world-class team of scientific founders and advisors, the company is advancing a preclinical pipeline with the goal of providing a broadly effective oral treatment for a patient population with high unmet need. Its inclusion in BioSpace's NextGen Class of 2026 highlights its potential as an emerging company to watch.
View full company profileTherapeutic Areas
Other Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Oxypurinol (XRX-OXY-301) | XORTX Therapeutics | Phase 3 |
| Undisclosed | GondolaBio | IND Enabling |
| Undisclosed Program | Calico | Phase 2 |
| Small Molecule Corrector Program | Renasant Bio | Pre-clinical |
| AL1311 | AceLink Therapeutics | Preclinical |
| PDE4 Allosteric Modulator Program | Mironid | Pre-clinical |